IL236197A0 - In vitro method for the diagnosis and surveillance of cancer - Google Patents

In vitro method for the diagnosis and surveillance of cancer

Info

Publication number
IL236197A0
IL236197A0 IL236197A IL23619714A IL236197A0 IL 236197 A0 IL236197 A0 IL 236197A0 IL 236197 A IL236197 A IL 236197A IL 23619714 A IL23619714 A IL 23619714A IL 236197 A0 IL236197 A0 IL 236197A0
Authority
IL
Israel
Prior art keywords
diagnosis
cancer
follow
vitro method
vitro
Prior art date
Application number
IL236197A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sotio As
Jirina Bartunkova
Radek Spisek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sotio As, Jirina Bartunkova, Radek Spisek filed Critical Sotio As
Publication of IL236197A0 publication Critical patent/IL236197A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • G01N33/4915Blood using flow cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57449Specifically defined cancers of ovaries
    • G01N33/57545
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051T-cell receptor (TcR)-CD3 complex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514CD4
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517CD8
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ecology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
IL236197A 2012-07-02 2014-12-11 In vitro method for the diagnosis and surveillance of cancer IL236197A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20120174539 EP2682750A1 (en) 2012-07-02 2012-07-02 In vitro method for the diagnosis and surveillance of cancer
US201261672941P 2012-07-18 2012-07-18
PCT/EP2013/063448 WO2014005909A1 (en) 2012-07-02 2013-06-27 In vitro method for the diagnosis and surveillance of cancer

Publications (1)

Publication Number Publication Date
IL236197A0 true IL236197A0 (en) 2015-01-29

Family

ID=46397089

Family Applications (1)

Application Number Title Priority Date Filing Date
IL236197A IL236197A0 (en) 2012-07-02 2014-12-11 In vitro method for the diagnosis and surveillance of cancer

Country Status (18)

Country Link
US (1) US20150337384A1 (enExample)
EP (2) EP2682750A1 (enExample)
JP (1) JP2015526709A (enExample)
KR (1) KR20150035521A (enExample)
CN (1) CN104364656A (enExample)
AU (1) AU2013286134A1 (enExample)
BR (1) BR112014026661A2 (enExample)
CA (1) CA2872668A1 (enExample)
CL (1) CL2014002975A1 (enExample)
EA (1) EA201500080A1 (enExample)
HK (1) HK1202618A1 (enExample)
IL (1) IL236197A0 (enExample)
IN (1) IN2015DN00678A (enExample)
MX (1) MX2014013079A (enExample)
PH (1) PH12014502436A1 (enExample)
SG (1) SG11201406581UA (enExample)
WO (1) WO2014005909A1 (enExample)
ZA (1) ZA201409298B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
JP6605506B2 (ja) 2014-02-24 2019-11-13 ヴェンタナ メディカル システムズ, インク. CD3、CD8、CD20及びFoxP3の同時検出によりがんに対する免疫応答をスコア化するための方法、キット、及びシステム
JP2017512493A (ja) * 2014-03-14 2017-05-25 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 癌のcd4+tヘルパー1型応答の監視方法および免疫回復
US20160266125A1 (en) * 2015-03-12 2016-09-15 John Wayne Cancer Institute Methods of treating and predicting progression of cancer based on t cell subsets
JP2018519295A (ja) * 2015-06-22 2018-07-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 粘膜固有層調節性t細胞の誘導
JP6100867B1 (ja) * 2015-11-06 2017-03-22 振武 曽 免疫状態の分析のための検査方法
CN106932576A (zh) * 2017-03-22 2017-07-07 山东大学深圳研究院 一种人调节性t细胞的免疫抑制功能的检测方法
EP3625565B1 (en) 2017-05-19 2022-11-30 Royal Melbourne Institute Of Technology Predicting responders to cyclophosphamide therapy
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CN108508196B (zh) * 2018-04-13 2020-10-27 何韶衡 一种检测人调节性t细胞亚型的试剂盒及检测方法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3103385A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
CN112740042B (zh) 2018-09-20 2025-05-23 文塔纳医疗系统公司 基于大小门控以分析流式细胞术数据

Also Published As

Publication number Publication date
MX2014013079A (es) 2014-12-08
EA201500080A1 (ru) 2015-06-30
WO2014005909A1 (en) 2014-01-09
EP2867677A1 (en) 2015-05-06
PH12014502436A1 (en) 2015-01-12
KR20150035521A (ko) 2015-04-06
JP2015526709A (ja) 2015-09-10
US20150337384A1 (en) 2015-11-26
CA2872668A1 (en) 2014-01-09
IN2015DN00678A (enExample) 2015-06-26
SG11201406581UA (en) 2015-01-29
CL2014002975A1 (es) 2015-04-24
CN104364656A (zh) 2015-02-18
AU2013286134A1 (en) 2015-01-22
EP2682750A1 (en) 2014-01-08
ZA201409298B (en) 2015-12-23
HK1202618A1 (en) 2015-10-02
BR112014026661A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
IL289821B (en) Compositions and methods for immunotherapy
IL272539B (en) Compositions and methods for immunotherapy
IL236197A0 (en) In vitro method for the diagnosis and surveillance of cancer
IL269045A (en) Aptamers and uses thereof
IL269166A (en) Methods and compositions for treating inflammation
ZA201605844B (en) Clinical outcome tracking and analysis
DK2917763T3 (da) Lidar-målesystem og lidar-målefremgangsmåde
IL244748B (en) Methods and processes for non-invasive assessment of genetic variations
HRP20181566T1 (hr) Biomarkeri raka i njihove uporabe
EP2962268A4 (en) SYSTEMS AND METHODS FOR ENHANCING CLINICAL DOCUMENTATION
HRP20180126T1 (hr) Pripravci pcsk9 irna i postupci njihove upotrebe
LT2847225T (lt) Antikūnai prieš klaudiną 18.2 tinkami vėžio diagnozavimui
IL244089A0 (en) Diagnostic methods and compositions for treatment of glioblastoma
PL2871944T3 (pl) Sposób perfuzji organu
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf
IL285527A (en) Compositions and methods for immunotherapy
HUE051632T2 (hu) Betegségek kezelésére szolgáló készítmények és eljárások
PL2997284T3 (pl) Sposób eksploatacji układu napędowego oraz układ napędowy
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
PL2742356T3 (pl) Środki prognostyczne w leczeniu nowotworów
IL232466A0 (en) Compositions and methods for prostate cancer analysis
FI20135866L (fi) Mikrobiologinen keratiinin prosessointi
EP3015864A4 (en) Biomarkers for the diagnosis and the response to treatment of pancreatic cancer
HUE047920T2 (hu) GD2-pozitív rák kezelésére szolgáló készítmények
LT2984108T (lt) Anti-s100a7 antikūnai, skirti vėžio gydymui ir diagnozei